245 related articles for article (PubMed ID: 29503141)
1. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
3. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.
Pickles T; Tyldesley S; Hamm J; Virani SA; Morris WJ; Keyes M
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):45-52. PubMed ID: 29029889
[TBL] [Abstract][Full Text] [Related]
6. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
[TBL] [Abstract][Full Text] [Related]
7. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
9. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
10. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
11. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
12. Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer.
Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
Urology; 2018 Apr; 114():147-154. PubMed ID: 29305198
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer.
Morgan KM; Riviere P; Nelson TJ; Guram K; Deshler LN; Sabater Minarim D; Duran EA; Banegas MP; Rose BS
JAMA Netw Open; 2024 Jun; 7(6):e2415911. PubMed ID: 38857047
[TBL] [Abstract][Full Text] [Related]
15. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
16. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
[TBL] [Abstract][Full Text] [Related]
17. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and cardiovascular risk.
Punnen S; Cooperberg MR; Sadetsky N; Carroll PR
J Clin Oncol; 2011 Sep; 29(26):3510-6. PubMed ID: 21844498
[TBL] [Abstract][Full Text] [Related]
19. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
